Antidepressant use and the risk of upper gastrointestinal bleeding in psychiatric patients: A nationwide cohort study in Taiwan

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 518-524

  Lee, Yen Chieh ^a   Shau, Wen Yi ^b   Chang, Chia Hsuin ^c,d   Chen, Shu Ting ^e   Lin, Min Shung ^a   Lai, Mei Shu ^c  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b Center for Drug Evaluation   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Statistics Office   (Taiwan)

Author keywords

Antidepressants; Gastrointestinal hemorrhage; Psychiatric disorder; Serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG INDUCED DISEASE; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL PATIENT; PRIORITY JOURNAL; PROPENSITY SCORE; REFERENCE DATABASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TAIWAN; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TAIWAN;

EID: 84863717527     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825ccd5a     Document Type: Article

References (30)

1. Chien IC, Bih SH, Chou YJ, et al. Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatr Serv. 2007;58:554-557.
2. Harman JS, Edlund MJ, Fortney JC. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv. 2009;60:611-616.
3. Moore M, Yuen HM, Dunn N, et al. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ. 2009;339:b3999.
4. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848-856.
5. Sihvo S, Isometsa E, Kiviruusu O, et al. Antidepressant utilisation patterns and determinants of short-term and non-psychiatric use in the Finnish general adult population. J Affect Disord. 2008;110:94-105.
6. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry. 1996;41:604-605.
7. Nelva A, Guy C, Tardy-Poncet B, et al. [Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants. Seven case reports and review of the literature]. Rev Med Interne. 2000;21:152-160. (Pubitemid 30099967)
8. de Abajo FJ, Montero D, Rodriguez LA, et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006;98:304-310.
9. Li N, Wallen NH, Ladjevardi M, et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997;8:517-523. (Pubitemid 28023394)
10. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009;7:1314-1321.
11. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59-64. (Pubitemid 36091601)
12. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-1109. (Pubitemid 29494721)
13. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65:795-803. (Pubitemid 351957705)
14. Dunn NR, Pearce GL, Shakir SA. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ. 2000;320:1405-1406.
15. Helin-Salmivaara A, Huttunen T, Gronroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol. 2007;63:403-408. (Pubitemid 46399132)
16. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008;17:328-335. (Pubitemid 351566348)
17. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66:76-81. (Pubitemid 351822152)
18. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104:1475-1482.
19. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005;22:175-181. (Pubitemid 41153059)
20. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655-658. (Pubitemid 32897004)
21. Vidal X, Ibanez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf. 2008;31:159-168. (Pubitemid 351158526)
22. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937-994.
23. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249-258. (Pubitemid 28022649)
24. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available at http://www.whocc.no/ ddd/definition-and-general-considera/. Accessed March 29,2010
25. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437-447.
26. Parsons LS. Reducing Bias in a Propensity Score-Matched Pair Sample Using Greedy Matching Techniques. Seattle, WA: Ovation Research Group; 2001.
27. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084-2106. (Pubitemid 43950281)
28. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007;134:1128-1135.
29. Jones MP. The role of psychosocial factors in peptic ulcer disease: beyond Helicobacter pylori and NSAIDs. J Psychosom Res. 2006;60:407-412.
30. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol. 2005;45:1106-1122. (Pubitemid 41361911)